A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis
Latest Information Update: 07 Oct 2024
At a glance
- Drugs CMK 389 (Primary)
- Indications Pulmonary sarcoidosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
Most Recent Events
- 11 Jan 2024 Status changed from active, no longer recruiting to completed.
- 22 Oct 2023 This trial has been completed in Denmark , according to the European Clinical Trials Database record.
- 20 Oct 2023 Planned End Date changed from 22 Dec 2023 to 19 Jan 2024.